Table 5.
Immunosuppressive drug doses
| Visit and characteristics, all parameters mg | CSA patients, mean ± SD (n) | TAC patients, mean ± SD (n) | P-value |
|---|---|---|---|
| Baseline | |||
| CNI | 323.0±101.5 (78) | 10.3±4.5 (72) | na |
| +MMF | 2803.0±918.0 (33) | 2300.7±902.0 (69) | 0.0116 |
| +mTOR | 1.3±0.4 (2) | 4.0±2.0 (3) | ns |
| +AZA | 88.4±25.1 (41) | — (0) | na |
| +steroids | 19.3±12.1 (77) | 30.4±13.7 (72) | <0.0001 |
| Month 6 | |||
| CNI | 260.6±72.4 (78) | 7.1±4.1 (72) | na |
| +MMF | 2750.0±908.7 (34) | 1810.3±680.7 (58) | <0.0001 |
| +Mycophenolate sodium | — (0) | 840.0±680.7 (3) | na |
| +mTOR | — (0) | 3.6±1.5 (11) | na |
| +AZA | 82.8±24.1 (32) | — (0) | na |
| +steroids | 6.4±3.1 (68) | 5.9±3.4 (63) | ns |
| Month 12 | |||
| CNI | 219.4±69.6 (78) | 5.7±3.4 (72) | na |
| +MMF | 2700.0±848.8 (45) | 1804.4±739.6 (46) | <0.0001 |
| +Mycophenolate sodium | — (0) | 1170.0±877.2 (5) | na |
| +mTOR | 3.2±4.1 (4) | 3.0±1.4 (20) | ns |
| +AZA | 74.0±34.2 (25) | — (0) | na |
| +steroids | 7.8±13.1 (54) | 3.8±2.9 (16) | 0.0411 |
| Month 24 | |||
| CNI | 193.1±62.3 (78) | 4.5±2.5 (72) | na |
| +MMF | 2779.4±869.8 (51) | 1625.0±670.5 (50) | <0.0001 |
| +Mycophenolate sodium | — (0) | 1260.0±496.2 (6) | na |
| +mTOR | 1.1±0.1 (4) | 3.0±1.3 (14) | <0.0001 |
| +AZA | 57.1±15.3 (14) | 50.0±35.4 (2) | ns |
| +steroids | 5.2±2.7 (34) | 2.6±1.5 (8) | 0.0017 |
Note: — indicates that there is no measured drug level.
Abbreviations: CSA, cyclosporine A; TAC, tacrolimus; SD, standard deviation; CNI, calcineurin inhibitor; na, not applicable; MMF, mycophenolat mofetil; mTOR, mammalian target of rapamycin inhibitor; ns, not statistically significant; AZA, azathioprine; n, number of patients.